Business Wire
-
Nuvation Bio Announces FDA Clearance Of Investigational New Drug Application For NUV-1511 For The Treatment Of Advanced Solid Tumors
1/8/2024
Nuvation Bio Inc. a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-1511, the first clinical candidate from the company’s novel drug-drug conjugate (DDC) platform.
-
Accenture Invests In QuantHealth To Accelerate Use Of AI-Powered Clinical Trial Simulations To Drive Cost-Effective Drug Development
1/8/2024
Accenture announced it has made a strategic investment, through Accenture Ventures, in QuantHealth, an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients.
-
Johnson & Johnson To Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates To Transform The Treatment Of Cancer
1/8/2024
Johnson & Johnson announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0B, or $1.9B net of estimated cash acquired.
-
U.S. Food And Drug Administration Approves ZELSUVMI As A First-In-Class Medication For The Treatment Of Molluscum Contagiosum
1/5/2024
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.
-
Nimbus Therapeutics Announces Expansion Of Its Immunology Drug Discovery Pipeline
1/5/2024
Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.
-
Better Therapeutics Announces Submission For FDA Breakthrough Device Designation For Digital Therapeutic Platform To Treat Liver Disease
1/2/2024
Better Therapeutics, Inc. a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD and NASH.
-
Diakonos Oncology Completes Phase 1 Glioblastoma Trial Recruitment; Receives FDA Orphan Drug Designation
1/2/2024
Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM).
-
Ceremorphic Announces New Life Sciences Division With New Design Methodology Based On Its Proprietary Analog And AI Technology That Can Significantly Reduce R&D Costs
10/24/2023
Ceremorphic, a fabless silicon and system development company, today announced the formation of a new life sciences division called “Ceremorphic Life Sciences,” which has been established to transform the entire drug discovery and development process.
-
X-Chem Acquires Glamorous AI — Immediately Creating A Leader In DEL-Powered AI Solutions
10/28/2021
X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.
-
Pfizer Establishes Precision Medicine Research Collaboration With Medco
11/1/2011
Pfizer Inc. (NYSE: PFE) announced recently that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes